From Maureen reply to snepal , i get a vibe that the cashflow report will not shine , hopefully accompanied with an operation overview/report which put us in a better light
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%